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Abstract Article Info 
Introduction: Locoregional failure of nasopharyngeal carcinoma (NPC) occurs despite the aggressive treatment 
that has been done. Optimal and accurate follow-up schedule after the radiotherapy or chemoradiotherapy 
sessions could improve the patient's quality of life (QoL).  
Discussion: Kwong et al. reported complete histological remission within 3 months after therapy and positive 
histological signs at >12 weeks considered a persistent disease. Kong et al. (2017) showed that the pathological 
treatment response using CT scan and MRI and stated that the median time to full regressions is 4.9 months. 
Some studies also reported that primary tumor continuously regressed >4 months after treatment and delayed 
remission >12 weeks is not a prognostic factor for poor survival.  
The use of MRI is superior to CT scan to detect residual or recurrent NPC. MRI showed good results in 
differentiating mature scar and tumor, whereas CT scan could not differentiate fibrosis and tumor because of 
the radiation therapy-induced inflammation. On the other hand, PET-CT has higher sensitivity compared to CT 
scan and MRI, but poor cost-effectiveness. Various studies and NCCN 2018 guidelines recommend the use of 
imaging between the third and sixth months after therapy to evaluate treatment response.   
Conclusion: Assessment of treatment-related late toxicities also an important factor to improve patient’s QoL. 
Evaluation of nutrition, speech difficulties, swallowing, hearing, dental care should be done annually and peer 
support groups can help improve patient’s QoL.  
Assessment of residual disease should be done at the minimum of 10 weeks after the completion of the therapy 
and long-term follow-up is a must because locoregional recurrences of NPC are common within the first two to 
three years after the treatment. 
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Nasopharyngeal carcinoma (NPC) is a malignant disease and one of the 
leading cause of death in several countries, including Indonesia with 7.391 
deaths in 2012 [1].  NPC is a highly radiosensitive malignancy and based on 
the guidelines of the National Comprehensive Cancer Network (NCCN) in 
2018, radiation therapy is the treatment of choice for primary NPC and 
concurrent chemoradiotherapy for locoregionally advanced NPC [2, 3].  
Despite the aggressive treatment, local or regional failure, and/or distant 
metastasis can occur in some patients. Thus, the accurate timing of evaluation 
of the treatment response is important in improving the patient's prognosis. Too 
early in evaluating the treatment response could result in overtreating, whereas 
too late in evaluating could result in poor salvage treatment outcome [4].  
High-dose radiotherapy and concurrent chemotherapy also induce acute 
and late toxicities. Where late toxicities can occur months, even years later 
after the treatment is complete. Therefore, close follow-up after the 
treatment completion is crucial for NPC patients and early detection of 
locoregional treatment failure is important as limited locoregional persistent 
or recurrent foci can usually be effectively salvaged [4]. However, there is 
no definite consensus for the optimal follow-up schedule for non-metastatic 
NPC patients. This review aims to discuss the optimal follow-up timing after 
chemoradiation therapy in nasopharyngeal carcinoma patients. 
 
2. MAIN TEXT 
2.1. Pattern of Pathological Response to Treatment 
Several studies reported that the cut-off times for treatment response 
vary from 1 to 4 months after a full course of radiotherapy or concurrent 
chemoradiotherapy. A study from Kwong DL et al. used serial biopsies to 
evaluate tumor regression patterns. As 803 NPC patients who completed 
radiotherapy treatment, underwent serial biopsies every 2 weeks for 3 months, 
they stated that 617 patients (76.8%) showed negative histology in the first 
session and 186 patients (23.2%) showed continuous spontaneous remission 
on repeat biopsies. In the end, 55 patients had persistent disease, 3 months 
after the treatment. In the total of 93.2% of the patients showed complete 
histological remission within 3 months after the radiation therapy. In this 
study, they use 12 weeks cut off, if the positive biopsy remains after 12 weeks,   
it considered persistent disease [5]. 
On the other hand, a study by Kong M et al. (2017) [6], showed that the 
median time to full regression after completion of therapy was 4.9 months. 
They used a CT scan and/or MRI to evaluate the tumor regression.                   
18 patients showed full regression after 3 months of the therapy and only      
8 patients showed full primary tumor regression within 3 months of the 
therapy. Some possible reasons for the different patterns of tumor regression 
between these two studies are the frequency and the way of evaluating the 
treatment response. Kwong DL et al. Study [5] started the evaluation from 
2 weeks after the treatment completion, whereas Kong M et al. evaluate 
every 1 to 2 months after the treatment completion. This could be the reason 
why the primary tumor regression detected later than the actual occurrence 
in M Kong et al. Study [6]. Besides, the histological process begins 
immediately after the exposure of the radiotherapy whereas clinical features 
may not significantly change immediately after the therapy, yet it will 
become apparent weeks or months after the exposure of the radiotherapy [6].  
Study by Lin et al. (2013) [7] stated that primary tumor eradication 
could continuously regressed for >4 months after the completion of 
chemoradiotherapy and delayed tumor regression is not associated with 
poor prognosis (Lv JW, 2017) [8]. Biopsies less than 3 months from the 
completion of the treatment showed a high rate of false positive. Several 
studies recommend waiting for at least 3 to 6 months and several studies 
recommend waiting for >4 months after the treatment completion for full 
regression of NPC if there are no signs of persistent or recurrent disease on 
follow-up sessions.  
 
 






2.2. Detection of Local, Regional, and Distant Treatment Failures and 
Recurrences 
2.2.1. Clinical Examination 
 
A thorough history taking and physical examinations have to be done 
during each follow-up sessions. History taking regarding signs and 
symptoms of recurrence NPC should be asked. Some patients with 
recurrence did not have specific symptoms and were found only at routine 
examinations. While most patients have symptoms such as bloody nasal 
discharge, headache, tinnitus, neck mass, nasal obstruction, hearing loss, 
blurred vision, facial edema, a sense that ears were plugged, epiphora, facial 
numbness, and abducens dysfunction. A study by Li JX et al. (2012) stated 
that nasal bloody discharge and headache are the most common symptoms 
for recurrent nasopharyngeal carcinoma [9].  
2.2.2. Endoscopy 
 
The use of nasopharyngoscopy after completion of radiotherapy treatment for 
evaluating local failure remains unclear. A study by Ragab et al. (2008) [10] showed 
that rigid endoscopy was useful for NPC’s post-treatment follow-up with sensitivity, 
specificity, positive predictive and negative predictive values of 66.6%, 95%, 
66.6%, and 95% respectively. High specificity and negative predictive value imply 
that endoscopic examination is good for the detection of residual or recurrent NPC. 
Whereas Kwong DL et al. (2001) study showed that the use of flexible endoscopy 
to detect recurrent NPC had low sensitivity, specificity, positive predictive and 
negative predictive values of 40.4%, 84.4%, 16.3%, and 95% [4]. 
A study by Bagri et al. (2013) [11] also showed high sensitivity, specificity, 
positive predictive and negative predictive values for rigid endoscopy examinations 
for post-treatment NPC patients; they were 77.78%, 93%, 70%, and 95.24% 
respectively.  Several studies stated that the rigid endoscopy is better than flexible 
endoscopy to detect residual or recurrent NPC after the treatment completion. It is 
because rigid endoscopy gives a wider field, better illumination, excellent 
resolution, and sharper image compared to flexible endoscopy. 
A study by Wang WH, 2011 reported the detection of mucosal recurrent 
nasopharyngeal carcinoma using white-light (WL) endoscopy compared to narrow-
band imaging (NBI). All suspected lesions detected by WL endoscopy were seen as 
granular or ulcerative lesions, whereas suspected lesions detected by NBI were seen 
as a brownish area with scattered brown spots. The study stated that the use of NBI 
endoscopy could improve the detection of recurrent mucosal NPC compared to WL 
endoscopy with sensitivity, specificity, positive predictive value, and negative 
predictive value fo WL endoscopy were 37.5%, 92.9%, 30%, 94.8% respectively. 
On the other hand, the results of recurrent NPC diagnosis by NBI view were as 
follows: sensitivity 87.5%, specificity 74.5%, positive predictive value 21.9%, and 
negative predictive value 98.6% [12]. 
In contrast, a study by Ng et al. (1999) stated that 28% of deep-seated recurrent 
NPC were not detected on endoscopy and it was diagnosed by magnetic resonance 
imaging (MRI). Recurrences in the submucosa or deeper structures are not 
accessible by endoscopy and the sensitivity decreases. Therefore, the use of 
endoscopy alone for early detection of local recurrence may not be sufficient [4]. 
2.2.3. Imaging for Locoregional Recurrence 
Imaging modalities that are commonly used for post-treatment follow-up 
are computed tomography (CT) scan, magnetic resonance imaging (MRI), and 
positron emission tomography (PET) scan. The use of head and neck CT scan 
after the treatment completion is common. However, the clinical value and 
optimal timing for CT scan are still debatable. CT scan cannot differentiate 
between post-treatment fibrosis, inflammation, edema from post-radiotherapy 
changes and residual or recurrent tumor [7, 8].  
Gong et al. study reported that MRI was superior to CT to detect residual or 
recurrent NPC after treatment.  MRI is great for differentiating mature scar tissue 
and tumor. However, the highest rates of false positive occur within one month 
after the radiation therapy. It was hypothesized that the inflammation response 
by radiation therapy caused a false positive diagnosis. Several studies stated that 
the inflammation would gradually disappear after the first three months from the 
completed therapy. Therefore, lots of studies and NCCN 2018 also recommend 
the use of imaging between the third to sixth months after the completion of the 
therapy to reduce false positive diagnosis [2].  
PET-CT has higher specificity than MRI and less influenced by 
inflammation caused by radiation therapy and higher sensitivity (95%) compared 
to CT (76%) and MRI (78%) in detecting locally residual or recurrent tumor [8]. 
Study by Yen et al (2006) [13] stated that PET has high sensitivity for detecting 
local, regional, and distant recurrences (91.6%, 90%, and 100% repectively) and 
high specificity (76%, 89%, and 90.6% respectively). Despite the high sensitivity 
and specificity, CT/MRI are preferred than PET scan because of the high cost. 
Yen et al. (2009) [14] suggested the use of PET or PET-CT as an additional 
imaging modality if CT or MRI showed uncertainly result [1]. The importance 
to assess the locoregional recurrence related to the evaluation of treatment 
success rate. The proper time in identification of locoregional recurrence could 
enhance the quality of life (QoL) due to the prognosis improvement.  [4].  
 
2.2.4. Imaging for Distant Metastases 
A study by Li AC, et al. (2015) [15], the most common site for 
nasopharyngeal carcinoma distant metastases are bone, lung, and liver 
respectively. The diagnosis can be made using multiple imaging modalities, such 
as chest c-ray and/or CT scan for the thorax, ultrasound and CT of the abdomen 
for liver metastases, and x-ray and/or bone scan for bone metastases. A study by 
Yen et al. (2006) [13] stated that Pet scan or PET/CT has higher sensitivity for 
diagnosing metastases in NPC compared to conventional work-up modalities. 
However, because of the poor cost-effectiveness of PET/CT, conventional work-
up modalities are still widely used nowadays [16, 17].  
NCCN guidelines recommend the use of imaging modalities (PET/CT or 
conventional modalities) for distant metastasis work-up in high-risk NPC 
patients, including nonkeratinizing histology, stage III-IV disease, N2-N3 
disease, and endemic phenotype [2]. Caglar et al. (2003) reported the use of bone 
scintigraphy prior to therapy and at 1-year intervals to evaluate bone metastasis [18]. 
2.2.5. Plasma EBV DNA & EBV Serology Measurement 
Plasma EBV DNA is one of the examinations included in the follow-up 
routine. A study by Lv JW, et al. (2017) [8] reported that detectable plasma 
EBV DNA at three months after the treatment completion was associated 
with the presence of tumor residue. It was found that the patients are prone 
to have residual tumor, local and distant failure if there is a detectable EBV 
DNA after the treatment. It was hypothesized that the plasma EBV DNA 
level represents the tumor DNA level [19]. 
2.2.6. Assessment of Treatment-Related Late Toxicities 
Assessment of the late toxicities related to radiation therapy also has to be 
done in the routine follow-up since late toxicities can occur weeks, months even 
weeks after the completion of the treatment. NPC patients often have difficulties 
in speech or hearing and swallowing, hence swallowing evaluation and 
rehabilitation are clinically indicated for post-treatment NPC patients. 
Sensorineural hearing loss also can be expected after platinum-based 
chemotherapy. Thyroid function screening tests also need to be conducted 
because radiation therapy could cause hypothyroidism. NCCN 2018 recommend 
checking thyroid-stimulating hormone (TSH) every 6 to 12 months after neck 
radiation therapy. Dental also care one of the important examinations because of 
osteoradionecrosis as one of the dental adverse events. And last but not least is 
patient support groups for cancer survivors because peer support also can 
improve quality of life of the patients and families [4].  
3. CONCLUSION 
Early detection of residual or recurrence NPC allows more treatment options 
to be considered. However, assessment of residual disease should be done at the 
minimum of 10 weeks after the completion of the therapy and long-term follow-
up is a must because locoregional recurrences of NPC are common within the 




Table 1. Post Treatment Follow-up Examinations Recommendation  
 
Modality Tests Schedule 
Clinical Physical examinations (including 
complete head and neck exam), 
Nasoendoscopy (WL and/or NBI 
view), Evaluation of speech, hearing, 
swallowing, and nutrition as indicated 
Year 1: every 1-3 months 
Years 2-3 : every 3 months 
Years 4-5 : every 6 months 
>5 years: every 12 months 
Laboratory TSH, free FT 4, Other endocrine tests 
as indicated, Plasma EBV DNA 
(optional) 
Every 6-12 months 
3 months after therapy 
Imaging MRI of the head and neck, Chest x-ray, 
CT of the thorax/abdomen, liver USG, 
bone scan, PET/CT scan when 
clinically indicated (metastases or 
uncertain result) 
3 months after therapy or within 
6 months after therapy, then 
annually (when clinically 
indicated) High-risk NPC, 
annually 
Others Smoking cessation and alcohol 
counseling , Dental care, Peer support 
group 
As clinically indicated 
3 months following RT 
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